PT - JOURNAL ARTICLE AU - Eilis Hannon AU - Gemma L Shireby AU - Keeley Brookes AU - Johannes Attems AU - Rebecca Sims AU - Nigel J Cairns AU - Seth Love AU - Alan J Thomas AU - Kevin Morgan AU - Paul T Francis AU - Jonathan Mill TI - Genetic risk for Alzheimer’s disease influences neuropathology and cognition via multiple biological pathways AID - 10.1101/2020.07.16.20149658 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.16.20149658 4099 - http://medrxiv.org/content/early/2020/07/17/2020.07.16.20149658.short 4100 - http://medrxiv.org/content/early/2020/07/17/2020.07.16.20149658.full AB - Alzheimer’s disease is a highly heritable, common neurodegenerative disease characterised neuropathologically by the accumulation of β-amyloid plaques and tau-containing neurofibrillary tangles. In addition to the well-established risk associated with the APOE locus, there has been considerable success in identifying additional genetic variants associated with Alzheimer’s disease. Major challenges in understanding how genetic risk influences the development of Alzheimer’s disease are clinical and neuropathological heterogeneity, and the high level of accompanying comorbidities. We report a multimodal analysis integrating longitudinal clinical and cognitive assessment with neuropathological data collected as part of the Brains for Dementia Research (BDR) study to understand how genetic risk factors for Alzheimer’s disease influence the development of neuropathology and clinical performance. 693 donors in the BDR cohort with genetic data, semi-quantitative neuropathology measurements, cognitive assessments and established diagnostic criteria were included in this study. We tested the association of APOE genotype and Alzheimer’s disease polygenic risk score - a quantitative measure of genetic burden - with survival, four common neuropathological features in Alzheimer’s disease brains (neurofibrillary tangles, β-amyloid plaques, Lewy bodies and TDP-43 proteinopathy), clinical status (clinical dementia rating) and cognitive performance (Mini-Mental State Exam, Montreal Cognitive Assessment). The APOE ε4 allele was significantly associated with younger age of death in the BDR cohort. Our analyses of neuropathology highlighted two independent pathways from APOE ε4, one where β-amyloid accumulation mediates the development of tauopathy, and a second characterized by direct effects on tauopathy independent of β-amyloidosis. Although we also detected association between APOE ε4 and dementia status and cognitive performance, these were all mediated by tauopathy, highlighting that they are a consequence of the neuropathological changes. Analyses of polygenic risk score identified associations with tauopathy and β-amyloidosis, which appeared to have both shared and unique contributions, suggesting that different genetic variants associated with Alzheimer’s disease affect different features of neuropathology to different degrees. Taken together, our results provide insight into how genetic risk for Alzheimer’s disease influences both the clinical and pathological features of dementia, increasing our understanding about the interplay between APOE genotype and other genetic risk factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementE.H., and J.M. were supported by Medical Research Council grant K013807. G.S. was supported by a PhD studentship from the Alzheimer's Society. The BDR is jointly funded by Alzheimer's Research UK and the Alzheimer's Society in association with the Medical Research Council. The South West Dementia Brain Bank is part of the Brains for Dementia Research program, jointly funded by Alzheimer's Research UK and Alzheimer's Society, and is also supported by BRACE (Bristol Research into Alzheimer's and Care of the Elderly) and the Medical Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:BDR was established as a Research Tissue Bank following application and approval by the National Research Ethics Service.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenetic, clinical and cognitive data are available through the Dementias Platform UK (DPUK; https://www.dementiasplatform.uk/) platform upon application. https://www.dementiasplatform.uk/ BDRBrains for Dementia ResearchCDRClinical Dementia RatingCERADConsortium to Establish a Registry for Alzheimer’s diseaseGWASgenome-wide association studiesLDlinkage disequilibriumLOADlate onset Alzheimer’s diseaseMMSEMini-Mental State ExaminationMoCAMontreal Cognitive AssessmentNIA-AANational Institute on Aging and Alzheimer’s AssociationNFTneurofibrillary tanglePRSpolygenic risk scoreQCquality controlSDstandard deviationSNPsingle nucleotide polymorphismTDP-43transactive response DNA-binding protein 43